Wednesday, July 8, 2020
Home Innovation That Matters

Innovation That Matters

OncoSenX Developing New Gene Therapy Approach that Kills Cancer Cells by “Suicide”

Gene therapy faced many challenges in its early days, but scientific advances, drug approvals and millions in investment have accelerated research in the gene therapy field. WuXi AppTec Communications has begun a new series profiling some of the companies developing novel and...

Advances in Targeted Therapies against Lung Cancer

Lung cancer was the leading cause of cancer death worldwide in 2012 according to WHO (World Health Organization, 2012) and the second most commonly diagnosed cancer in both men and women. Smoking is the most convincing risk factor that contributes to the development of...

WuXi AppTec Named One of MIT Technology Review’s 50 Smartest Companies

  Shanghai, June 29, 2019 – WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review’s 50 Smartest Companies (TR50) for 2019....

WuXi AppTec’s Enabling Capability Recognized by Partners and Philadelphia Authority at BIO 2019

By WuXi Content Team WuXi AppTec’s enabling capabilities and contribution to the development of life science were recognized by both its many partners and the City of Philadelphia at the BIO International Convention 2019. The BIO International Convention is hosted annually by the Biotechnology Innovation Organization...

The Future of Cancer Therapy: An Interview with Yinon Ben-Neriah, Hebrew University

Dr. Yinon Ben-Neriah is Professor of Immunology and Cancer Research at the Lautenberg Center of Immunology, Hebrew University Medical School in Jerusalem.  Dr. Ben-Neriah obtained his MD from Tel Aviv University and PhD from the Weizmann Institute of Science. He completed his postdoctoral training...

SUBSCRIBE TO OUR NEWSLETTER

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WuXi NEWS